Ponatinib

Home/Tag: Ponatinib

Ponatinib Found to Have Therapeutic Potential for Drug-Resistant KIT mutations in GIST

A recent article in the Clinical Cancer Research Journal discussed a new drug, Ponatinib, that shows therapeutic potential for drug-resistant KIT mutations in GIST.

By |2019-09-20T13:34:35-04:00October 3rd, 2014|News, Patient Support, Research|

FDA asks ARIAD to suspend marketing and sales of Iclusig (ponatinib)

The U.S. Food and Drug Administration (FDA) has asked ARIAD Pharmaceuticals, the manufacturer of Iclusig (ponatinib) to suspend marketing and sales of ponatinib because of the risk of life-threatening blood clots and severe narrowing of [...]

By |2019-09-20T11:38:58-04:00November 1st, 2013|Drug Treatment, News|

ARIAD Ponatinib Trial Pauses Accepting New Patients

ARIAD has announced that their ponatinib (Iclusig) trial, which some GIST patients are participating in, has paused new enrollment based on consultations with the FDA regarding patients who experienced particular vascular events. Subject to agreement with [...]

By |2019-09-20T11:44:57-04:00October 10th, 2013|Clinical Trials, News|
Go to Top